Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials

  • 1.
    • US Food and Drug Administration

    Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.

  • 2.
    • International Council for the Harmonization of Technical Requirements for Pharmaceuticals for Human Use

    E9(R1) Statistical principles for clinical trials: addendum: estimates and sensitivity analysis in clinical trials.

  • 3.
    • Coen C
    • Pe M
    • AC Duck
    • et al.

    International standards for the analysis of quality of life and patient-reported outcomes in randomized controlled cancer trials: recommendations from the SISAQOL consortium.

    Lancet Oncol. 2020; 21: e83-e96

  • 4.
    • Fiero MH
    • Roydhouse JK
    • Vallejo J.
    • King-Kallimanis BL
    • Kluetz PG
    • Sridhara R

    United States Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January 2008 and December 2017.

    Lancet Oncol. 2019; 20: e582-e589

  • 5.
    • Pe M
    • Sleep L
    • Coen C
    • et al.

    Statistical analysis of patient-reported outcome data in randomized controlled trials of locally advanced and metastatic breast cancer: a systematic review.

    Lancet Oncol. 2018; 19: e459-e469

  • 6.
    • Eckhardt SG
    • De Porre P.
    • Smith D
    • et al.

    Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.

    J Manage pain symptoms. 2009; 37: 135-143

  • 7.
    • Wilson MK
    • Friedlander ML
    • Joly F
    • Oza AM

    A systematic review of reports on health-related quality of life in phase III ovarian cancer clinical trials: room for improvement.

    Oncologist. 2018; 23: 203-213

  • 8.
    • US Food and Drug Administration

    Oncology Drug Advisory Committee Brief BLA 125477/S34 ramucirumab.

  • 9.
    • Fernandes LL
    • Zhou J
    • Kanapuru B
    • et al.

    Review of patient-reported outcomes in multiple myeloma registration trials: highlighting areas for improvement.

    J blood cancer. 2021; 11: 148

  • ten.
    • Note A
    • Hamidou Z
    • Paget-Bailly S
    • et al.

    Time to deterioration of health-related quality of life score as a longitudinal analysis modality for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? .

    Qual Life Res. 2015 ; 24: 5-18

  • 11.
    • Harrington KJ
    • Ferris RL
    • Blumenschein Jr, G
    • et al.

    Nivolumab versus standard monotherapy of investigator’s choice in relapsed or metastatic head and neck squamous cell carcinoma (CheckMate 141): health-related quality of life results from a randomized phase 3 trial.

    Lancet Oncol. 2017; 18: 1104-1115

  • 12.
    • Roydhouse JK
    • Bhatnagar V
    • Fiero MH
    • et al.

    To assess time to progression of pain in multiple myeloma.

    Blood. 2018; 132 2299

  • 13.
    • Charton E
    • Cuer B
    • Cotton F
    • et al.

    Time to deterioration in randomized cancer clinical trials for patient-reported outcome data: a systematic review.

    Qual Life Res. 2020; 29: 867-878

  • 14.
    • International Council for the Harmonization of Technical Requirements for Pharmaceuticals for Human Use

    E9 Statistical principles for clinical trials.

  • 15.
    • Akacha M
    • Bretz F
    • Ruberg S

    Estimands in clinical trials – broadening the perspective.

    StatMed. 2017; 36: 5-19

  • 16.
    • Mallinckrodt C
    • Bell J
    • Liu G.
    • et al.

    Aligning Estimators with Estimators in Clinical Trials: Putting ICH E9(R1) Guidelines into Practice.

    Ther Innov Regul Sci. 2020; 54: 353-364

  • 17.

    A taxonomy of estimates for regulatory clinical trials with interruptions.

    StatMed. 2016; 35: 2865-2875

  • 18.

    Defining treatment effects: a regulatory perspective.

    Clinical tests. 2019; 16: 345-349

  • 19.
    • Ratitch B
    • Bell J
    • Mallinckrodt C
    • et al.

    Choice of estimands in clinical trials: implementation of ICH E9(R1).

    Ther Innov Regul Sci. 2020; 54: 324-341

  • 20.
    • Fiero MH
    • Pe M
    • Weinstock C
    • et al.

    Demystifying the estimation framework: a case study using patient-reported outcomes in oncology.

    Lancet Oncol. 2020; 21: e488-e494

  • 21.
    • US Food and Drug Administration

    Public Orientation Workshop on Patient-Oriented Drug Development: Integrating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making.

  • 22.

    Contribution of early endpoints of clinical benefit to decreased lung cancer mortality rates.

    JAMA Oncol. 2021; 7: 829-830

  • 23.
    • Howlader N
    • Forjaz G
    • Mooradian MJ
    • et al.

    The effect of advances in lung cancer treatment on population mortality.

    N Engl J Med. 2020; 383: 640-649

  • 24.

    Key lung cancer statistics.

  • 25.
    • LeBlanc TW
    • Nickolich M
    • CN rushes
    • Samsa’s GP
    • Locke S.C.
    • Abernethy PA

    What bothers lung cancer patients the most? A prospective electronic longitudinal study of patient-reported outcomes in advanced non-small cell lung cancer.

    Cancer Care Support. 2015 ; 23: 3455-3463

  • 26.
    • AM wall
    • JC Weeks
    • Kahn KL
    • et al.

    Prevalence of symptoms in patients with lung and colorectal cancer.

    J Manage pain symptoms. 2015 ; 49: 192-202

  • 27.

    114th US Congress. 21st Century Remedies Act.

  • 28.
    • US Food and Drug Administration

    FDA’s series of patient-centered drug development guidance to improve the integration of the patient’s voice into medical product development and regulatory decision-making.

  • 29.
    • US Food and Drug Administration

    Qualification Program for Clinical Outcome Assessment (COA).

  • 30.
    • US Food and Drug Administration

    Qualification Process for Drug Development Tools: Guidance for Industry and FDA Staff.

  • 31.
    • US Food and Drug Administration

    Key Patient-Reported Outcomes in Cancer Clinical Trials: Guidance for Industry – Draft Guidance.

  • 32.

    Roydhouse J, Kluetz P, King-Kallimanis B. Time to endpoint deterioration in oncology clinical trials. Advance the science of endpoints; September 20-21, 2018.

  • 33.
    • Eisenhauer EA
    • Therasse P
    • Bogaerts J
    • et al.

    New response endpoints in solid tumours: revised RECIST guideline (version 1.1).

    Eur J Cancer. 2009; 45: 228-247

  • 34.
    • King-Kallimanis BL
    • Lederer NM
    • Kim J.
    • et al.

    Patient-Reported Outcomes After Discontinuation of Treatment: Commercial Clinical Trial Data on Four Types of Cancer.

    Value health. 2021; 24: 1302-1307

  • 35.
    • Fleming TR
    • Dr. Rothmann
    • Lu HL

    Issues with the use of progression-free survival when evaluating oncology products.

    J Clin Oncol. 2009; 27: 2874-2880

  • 36.

    Practical and statistical issues related to missing data for patient-reported longitudinal outcomes.

    Statistical methods Res. med. 2014 ; 23: 440-459

  • 37.
    • National Research Council

    Prevention and treatment of missing data in clinical trials.

    National Academies Press,
    washington d.c.2010

  • 38.

    Quantification of treatment effect for time-to-event parameters: estimates, analysis strategies and beyond.

    PharmStat. 2019; 18: 145-165

  • 39.
    • Degtyarev E
    • Rufibach K
    • Shentu-Y
    • et al.

    Assessment of the impact of COVID-19 on the purpose of clinical trials and analysis of clinical trials in oncology – application of the Estimand framework.

    Stat Biopharm Res. 2020; 12: 427-437

  • 40.
    • Casey M
    • Degtyarev E
    • Lechuga MJ
    • et al.

    Estimand framework: are we asking the right questions? A case study in the setting of a solid tumor.

    PharmStat. 2021; 20: 324-334

  • 41.
    • US Food and Drug Administration

    Clinical trial endpoints for approving cancer drugs and biologics: guidance for industry.

  • 42.

    Quality of life: evaluation, analysis and interpretation of results reported by patients.

    John Wiley and sons,
    New York, NY2013

  • 43.

    The role of statistics in regulatory decision-making.

    Ther Innov Regul Sci. 2014 ; 48: 10-19

  • Comments are closed.